Latest News and Blogs

Congenica appoints Dr. Sam Roberts as Non-Executive Director to the Board. Sam is the Managing Director of Health & Care at Legal & General.

New Funds to Drive Further Commercialisation of Rare and Inherited Cancer Applications and Expansion into Oncology, Wellness and Pharma Collaborations

Congenica CEO David Atkins PhD is joined by Chairman Andy Richards OBE in announcing the company's Series C fundraise.

Congenica's new module accelerates research into the relationship between an individual’s genomic variation & COVID-19 susceptibility & clinical outcomes.

Congenica launches an update that will provide automated classification, evidence and reporting of recurrent ‘known’ variants, significantly saving time.

Sequencing and analysis of whole genomes in the 100,000 Genome Project led to the genetic diagnosis for 60% of patients with rare diseases.

Following a rigorous evaluation, Congenica was selected as the exclusive clinical decision support provider for the UK Genomic Medicine Service.

Congenica launches Congenica Prenatal, a new application that facilitate faster, more accurate and comprehensive molecular research into fetal anomalies.

Genomics England has announced a major new sequencing project to uncover how a person’s genetic make-up influences their susceptibility to COVID-19.

With case loads increasing every day, clinical teams are experiencing increasing pressure to make their variant interpretation more efficient.

Congenica today announced the launch of Congenica Neuro, a new application to enable faster analysis of epilepsy and neurodevelopmental disorders.

Congenica has been named MedTech Company of the Year 2019 at the Cambridge Independent Science and Technology Awards 2019 at a ceremony held in Cambridge.